A pharmaceutical company known as a global leader in consumer healthcare operates a significant prescription pharmaceutical business. Its consumer healthcare portfolio includes over 250 products and generates approximately USD 2.4 billion in sales annually. In recent years, the firm launched an internal innovation unit that was established with the mission of developing new businesses through open innovation or by acquiring new technologies. The firm focuses on early-stage innovation, particularly seed and Series A companies, and explores opportunities via direct investment as well as collaborative research and product licensing.
The firm targets transformative concepts in healthcare, such as preventative technologies, non-invasive treatments, and early diagnostic tools. The firm typically invests between USD 300,000 and USD 5 million, though the firm does not lead investment rounds. The firm prefers to invest alongside a lead VC or within a syndicate of investors. The firm’s geographic focus lies predominantly in North America and Europe.
The firm has outlined three priority areas of interest: (1) technologies “beyond the pill,” which includes digital therapeutics, software-based interventions, and medical devices, with a strong emphasis on neurotechnology such as neuromodulation, neurofeedback, and biofeedback; (2) advanced therapies, encompassing novel modalities and emerging therapeutic approaches; and (3) sensing and monitoring technologies, including wearables and vital sign sensing. While the firm does not require board representation, it may seek observer rights when appropriate.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment